|
Pronunciation |
|
(a
DEF o
veer) |
|
|
U.S. Brand
Names |
|
Preveon™ |
|
|
Generic
Available |
|
No |
|
|
Pharmacological Index |
|
Antiretroviral Agent, Reverse Transcriptase Inhibitor
(Nucleoside) |
|
|
Use |
|
Investigational (8/1/98); treatment of HIV infections in combination with at
least two other antiretroviral agents; also has some activity against hepatitis
B virus and herpes viruses |
|
|
Pregnancy Risk
Factor |
|
Not available |
|
|
Adverse
Reactions |
|
Endocrine & metabolic: Elevation of transaminases, hot flashes
Gastrointestinal: GI symptoms
Genitourinary: Urethritis
Hematologic: Elevation of hemoglobin |
|
|
Mechanism of
Action |
|
Acyclic nucleotide reverse transcriptase inhibitor which interferes with HIV
viral RNA dependent DNA polymerase resulting in inhibition of viral
replication |
|
|
Pharmacodynamics/Kinetics |
|
Serum half-life: 1.6 hours; 16-18 hours intracellularly |
|
|
Usual Dosage |
|
Oral:
Hepatitis B: 125 mg once daily |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
No effects or complications reported |
|
|
Patient
Information |
|
This is not a cure for AIDS or AIDS complex, nor will it reduce the risk of
transmission to others. Long-term effects are not known. You may need frequent
blood tests to adjust dosage for maximum therapeutic effect. Take as directed,
for full course of therapy; do not discontinue (even if feeling better). You may
experience hot flashes (cool environment or cool clothes may help); nausea or
vomiting (small, frequent meals, chewing gum, or sucking on lozenges may help);
difficulty breathing; or rash. Inform prescriber if you are or intend to be
pregnant. Do not breast-feed. |
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|